Gabapentin and Pegintron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gabapentin (gabapentin) and Pegintron (peginterferon alfa-2b). Common drug interactions include anxiety among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Gabapentin and Pegintron. It is created by eHealthMe based on reports of 34 people who take the same drugs from the FDA, and is updated regularly.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in peripheral neuropathy. eHealthMe is studying from 322,990 Gabapentin users. Check the latest studies of Gabapentin.

What is Pegintron?

Pegintron has active ingredients of peginterferon alfa-2b. It is often used in hepatitis c. eHealthMe is studying from 10,326 Pegintron users. Check the latest studies of Pegintron.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 01, 2026

34 people who take Gabapentin and Pegintron together, and have interactions are studied.

Gabapentin and Pegintron drug interactions.

What are the common drug interactions of Gabapentin and Pegintron, by gender? *:

female:

  1. Anxiety
  2. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  3. Back disorder
  4. Balance disorder
  5. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  6. Chest pain
  7. Cryoglobulinaemia (blood contains large amounts of cryoglobulins - proteins)
  8. Decreased appetite
  9. Dehydration (dryness resulting from the removal of water)
  10. Disturbance in attention

male:

  1. Fatigue (feeling of tiredness)
  2. Asthenia (weakness)
  3. Weight decreased
  4. Bone pain
  5. Alopecia (absence of hair from areas of the body)
  6. Anaemia (lack of blood)
  7. Back pain
  8. Diarrhoea
  9. Dizziness
  10. Headache (pain in head)

What are the common drug interactions of Gabapentin and Pegintron, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Influenza like illness
  2. Bone pain
  3. Chills (felling of cold)
  4. Dysgeusia (disorder of the sense of taste)
  5. Fatigue (feeling of tiredness)
  6. Haematocrit decreased
  7. Headache (pain in head)
  8. Malaise (a feeling of general discomfort or uneasiness)
  9. Neuropathy peripheral (surface nerve damage)
  10. Platelet count decreased

40-49:

n/a

50-59:

  1. Rash
  2. Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
  3. Rash pruritic (redness with itching)
  4. Renal failure acute (rapid kidney dysfunction)
  5. Rhinorrhoea (watery mucus discharge from the nose)
  6. Scab (a hard coating on the skin formed during the wound healing)
  7. Skin ulcer haemorrhage (bleeding skin ulcer)
  8. Social avoidant behaviour (avoiding social connection a personality disorder)
  9. Somnolence (a state of near-sleep, a strong desire for sleep)
  10. Staring (a prolonged gaze or fixed look)

60+:

  1. Fatigue (feeling of tiredness)
  2. Anaemia (lack of blood)
  3. Choking (mechanical obstruction of the flow of air from the environment into the lungs)
  4. Coma (state of unconsciousness lasting more than six hours)
  5. Dyspepsia (indigestion)
  6. Fall
  7. Hypoxia (low oxygen in tissues)
  8. Infection
  9. Insomnia (sleeplessness)
  10. Malaise (a feeling of general discomfort or uneasiness)

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 3 people, 8.82%
  2. Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 2 people, 5.88%
  3. Neuropathy Peripheral (surface nerve damage): 2 people, 5.88%
  4. Gastric Disorder (disease of stomach): 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and Pegintron?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Gabapentin and Pegintron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gabapentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pegintron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gabapentin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pegintron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on gabapentin and peginterferon alfa-2b (the active ingredients of Gabapentin and Pegintron, respectively), and Gabapentin and Pegintron (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: